Almost 600,000 GlaxoSmithKline inhalers have been recalled nationwide.
According to the U.S. Food and Drug Administration, the GSK inhalers are being recalled for a defective delivery system.
The inhalers were recalled on March 22 and classified as a Class II recall. According to the FDA, this means the "product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote."
The FDA says that some inhalers are "out of specification results for leak rate." They were made at a GSK plant in Zebulon, North Carolina.